Introduction {#Sec1}
============

Head and neck cancers consist approximately 6 % of all cancer cases in Poland with nearly six thousand new cases annually \[[@CR1], [@CR2]\]. Despite recent advancements in oncology, the five-year survival rates in head and neck cancers have remained unchanged and are estimated overall around 50--60 %. The prognosis is much worse in the case of patients suffering from more advanced (regional and distant) tumors. New therapeutic strategies and diagnostic markers are necessary for the improvement of treatment outcomes. The molecular biology of head and neck squamous cell carcinomas (HNSCC) which are the most prevalent type of head and neck malignancy is increasingly well understood what currently forms the basis for the search of both new biomarkers and novel chemotherapeutic strategies. Among the many molecular aberrations observed in HNSCC, changes in the activity of signaling pathways such as TGFβ, Ras/PI3K/AKT/mTOR, Notch, or NFκB which are responsible for the regulation of cell proliferation, migration, and cell death emerge as important factors associated with both the pathogenesis and progression of the disease \[[@CR3]--[@CR5]\]. Recently, aberrations in the function of sonic hedgehog (Shh) and canonical Wnt pathways have been also implicated in the development of HNSCC.

Canonical Wnt signaling regulates the nuclear translocation of β-catenin. In unstimulated cells, β-catenin is sequestered in the cytoplasm by an inhibitory complex which consists of axin, APC, casein kinase and glycogen synthase kinase---GSK3β. In these conditions, β-catenin undergoes phosphorylation and is targeted for proteasomal degradation. The binding of Wnt ligands to membrane frizzled/LRP receptors causes the destabilization of the inhibitory complex via activation of disheveled and leads to the release of β-catenin which enters the nucleus and binds to TCF/LEF transcription factors. This stimulates the transcription of various genes responsible for cell cycle regulation and cell migration including *CCND1* (encoding cyclin D1)*, survivin, MMP-7* (encoding matrix metalloproteinase 7), and *c-Myc* \[[@CR6]\]. The precise regulation of the pathway is also secured by the activity of a group of proteins which antagonize the progression of the pathway in a stage-specific manner. The activation of canonical Wnt pathway is detected already in precancerous lesions \[[@CR7], [@CR8]\], and its dysregulation may increase with tumor progression attributing to enhanced cancer cell migration and thus worse prognosis \[[@CR9]--[@CR11]\]. The activation of Wnt signaling in HNSCC is rarely the result of genetic mutations but usually occurs due to the hypermethylation of genes encoding the negative regulators of the pathway \[[@CR12]--[@CR15]\]. The methylation of Wnt pathway antagonists such as *SFRP1--5*, *DKK1--3*, *WIF1*, *DACH1*, and *PPP2R2B* has been frequently observed, and it was associated with worse prognosis \[[@CR15]--[@CR18]\]. The biological importance of Wnt dysregulation for the development of HNSCC is corroborated by the fact that the growth of tongue cancer cells is inhibited by the silencing of *CTNNB1* gene which encodes β-catenin \[[@CR19]\].

Sonic hedgehog is another signaling pathway active in embryonal and somatic stem cells which undergoes activation in human cancers \[[@CR20]\] and may have crosstalk with Wnt signaling. The binding of Shh ligand to patched (*PTCH1*) protein relieves the inhibition of smoothened (SMO) which is then able to relieve the sequestration of a Gli1 transcription factor by a cytoplasmic complex which includes SUFU (suppressor of fused homolog). This subsequently induces Gli1 translocation to the nucleus where it stimulates the expression of genes related to cell proliferation and cell cycle regulation. Evidence for the implication of Shh pathway dysregulation in the pathogenesis of HNSCC has only recently started to accumulate \[[@CR21]--[@CR24]\]. Importantly, Shh activation was associated with disease progression and worse prognosis in oral squamous cell carcinoma (OSCC) \[[@CR25]\]. Based on these findings, Shh signaling has been indicated as a new therapeutic target in this tumor type \[[@CR26]\]. Indeed, treatment of HNSCC cells with Shh inhibitor cyclopamine suppressed cell growth and enhanced the cytotoxic effects of cisplatin and docetaxel \[[@CR27]\]. However, the molecular mechanisms leading to the activation of Shh in HNSCC have not been well studied although it is suggested that this may occur due to epigenetic changes \[[@CR28]\].

The association between the dysregulation of Wnt and Shh pathways and the pathogenesis of HNSCC implicates the possibility of therapeutic targeting HNSCC by modulating the activity of these pathways. This however requires a thorough understanding of the molecular mechanisms which lead to pathway activation, and epigenetic mechanisms have emerged as the possibly most important factor which attributes to this phenomenon. Relatively, much is known about the effect of epigenetic silencing of several negative regulators of Wnt pathway on its activation in HNSCC although the studies have focused only on few regulatory genes so far. On the other hand, the contribution of epigenetic mechanisms to Shh activation in HNSCC has not been well studied and requires exploration. Most importantly, epigenetic silencing of negative regulators of Wnt and Shh pathways may have diagnostic significance. Thus, the aim of the present study was to assess the frequency of methylation of the selected negative regulators of Wnt signaling: *CXXC4*, *DACT2*, *HDPR1* (*DACT1*), and *FBXW11* and Shh signaling: *HHIP*, *PTCH1*, *SUFU*, *ZIC1*, and *ZIC4* which were either rarely or never under study in head and neck cancers previously and correlate it with clinicopathological features in a group of HNSCC patients.

Materials and methods {#Sec2}
=====================

Cell lines {#Sec3}
----------

Thirty-six cell lines which were derived from squamous cell carcinomas of the head and neck region at the University of Turku, Finland \[[@CR29]\] were analyzed. The characteristics of the patients whose surgically removed tumor sections were used for the establishment of the respective cell lines are presented in Table [1](#Tab1){ref-type="table"}.Table 1Characteristics of the patients and the derived cell linesName of cell lineSexAgePrimary tumor locationTNM stagingSpecimen siteType of lesionHistological gradeUT-SCC-4F43Hypopharynx/supraglottic larynxT~3~N~0~M~0~NeckmetG2UT-SCC-6AF51Supraglottic larynxT~2~N~1~M~0~LarynxrecG1UT-SCC-6BF51Supraglottic larynxT~2~N~1~M~0~NeckmetG1UT-SCC-7M67Skin (temporal region)T~1~N~0~M~0~NeckmetG2UT-SCC-8M42Supraglottic larynxT~2~N~0~M~0~LarynxpriG1UT-SCC-10M62Tongue sccT~1~N~0~M~0~TonguepriG2UT-SCC-16AF77Tongue sccT~3~N~0~M~0~TonguepriG3UT-SCC-16BF77Tongue sccT~3~N~0~M~0~NeckmetG3UT-SCC-17M65Supraglottic larynxT~2~N~0~M~0~SternummetG3UT-SCC-19AM44Glottic larynxT~4~N~0~M~0~LarynxpriG2UT-SCC-19BM44Glottic larynxT~4~N~0~M~0~Larynxpri (per)G2UT-SCC-20AF58Floor of mouthT~1~N~0~M~0~Floor of mouthpri (per)G2UT-SCC-20BF58Floor of mouthFloor of mouthresidG2UT-SCC-22M79Glottic larynxT~1~N~0~M~0~LarynxrecG2UT-SCC-23M66Transglottic larynxT~3~N~0~M~0~Larynxpri (per)G1UT-SCC-24AM41Tongue sccT~2~N~0~M~0~TonguepriG2UT-SCC-24BM41Tongue sccNeckmet (per)G2UT-SCC-29M82Glottic larynxT~2~N~0~M~0~LarynxpriG1UT-SCC-34M63Supraglottic larynxT~4~N~0~M~0~Supraglottic larynxpriG1UT-SCC-35M50Glottic larynxT~2~N~0~M~0~LarynxresidG2UT-SCC-36M46Floor of mouthT~4~N~1~M~0~Floor of mouthpriG3UT-SCC-38M66Glottic larynxT~2~N~0~M~0~LarynxpriG2UT-SCC-45M76Floor of mouthT~3~N~1~M~0~Floor of mouthpriG3UT-SCC-47M78Floor of mouthT~2~N~0~M~0~Floor of mouthpriG3UT-SCC-56M62Floor of mouthT~x~N~2~M~0~Floor of mouthrecG2--G3UT-SCC-58M63Transglottic larynxT~4~N~1~M~0~Neckmet (skin)G1UT-SCC-85M55Tongue sccT~3~N~0~M~0~Tongue floor of mouthrecG2UT-SCC-90M35Tongue sccT~1~N~0~M~0~Floor of mouthrec/metG2UT-SCC-100M70Gingival sccrT~3~Mucosae bucchaerecG3UT-SCC-103M51Glottic larynxT~3~N~0~M~0~Larynxpri (per)G2UT-SCC-104M80Supraglottic larynxT1N~2A~M~0~NeckmetG2UT-SCC-106AM59Glottic larynxT~1A~N~0~M~0~LarynxpriG2UT-SCC-106BM59Glottic larynxrT~3~N~0~M~0~LarynxrecG3UT-SCC-107M46Supraglottic larynxT~4~N~2C~M~0~LarynxpriG2UT-SCC-108M68Supraglottic larynxT~2~N~0~M~0~LarynxpriG3UT-SCC-116M60Supraglottic larynxT~4~N~1~M~0~LarynxpriG2*F* female, *M* male, *scc* squamous cell carcinoma, *pri* primary, *per* persistent, *rec* recurrent, *met* metastasis, *resid* residual

Patients {#Sec4}
--------

The study group consisted of 42 patients with primary oral/oropharyngeal squamous cell carcinoma (localized mostly in tongue or tonsils) and 30 patients with primary laryngeal squamous cell carcinoma (LSCC) who were primarily treated surgically at the Department of Otolaryngology and Laryngological Oncology, Poznan University of Medical Sciences. In the case of oral cancer patients, a tumor section along with a fragment of macroscopically normal surgical margin was obtained from each patient for analysis. Only tumor sections which contained at least 80 % of cancer cells were qualified for further investigation. Patient follow-up observation usually covered at least 3 years post-operation. Eighteen OSCC and 12 LSCC patients died of the disease during follow-up. The study was approved by the local ethics committee at Poznan University of Medical Sciences. The clinical characteristics of the study group are presented in Table [2](#Tab2){ref-type="table"}.Table 2Clinical characteristics of patients in the study groupOSCCLSCCAgeRange28--8439--79Mean5757SexFemale42Male3828TNM stagingT140T2232T3817T4711N02021N1134N275N320M04230G histological stageG198G22621G371Overall survival time (months)Range0--724--93Mean3054Tumor-related death1812OtherRecurrence611Metastasis11Second primary tumor20

Methylation-specific PCR {#Sec5}
------------------------

DNA samples from the early passage cell lines and from a clinical material were prepared using standard phenol/chloroform extraction protocol. Methylation-specific PCR (MSP) was used for the analysis of gene promoter methylation \[[@CR30]\]. Prior to amplification, all the DNA samples underwent bisulfite conversion using an EZ DNA methylation Kit (ZymoResearch, USA) according to manufacturer's protocol. Primer sequences for the analysis of *CXXC4*, *FBXW11*, *SUFU*, *ZIC1*, and *ZIC4* were designed using the MethPrimer online software \[[@CR31]\] and are presented in Table [3](#Tab3){ref-type="table"}. Primer sequences used for the analysis of *DACT2*, *HDPR1*, *HHIP*, and *PTCH1* were previously described \[[@CR32]--[@CR35]\]. All the primers were obtained from the oligonucleotide synthesis facility at the Institute of Biochemistry and Biophysics, Polish Academy of Sciences. DNA derived from white blood cells of healthy donors and fully methylated human genomic DNA (Thermo Scientific, USA) were used as negative and positive MSP controls, respectively. Moreover, samples of genomic DNA extracted from early passage primary culture of human oral keratinocytes and human tracheal epithelial cells (ScienCell Research Laboratories, USA) were used as normal controls for comparison. PCR reactions were performed in a T100 thermal cycler (Bio-Rad Laboratories, USA) using HOT FIREPol Polymerase (Solis BioDyne, Estonia). The amplification protocol was as follows: initial enzyme activation for 15 min at 95 °C followed by 40 cycles of 95 °C for 30 s, *X*°C for 30 s and 72 °C for 30 s, and the final elongation at 72 °C for 5 min, where *X* stands for the appropriate annealing temperature as described in Table [3](#Tab3){ref-type="table"}. PCR products were resolved on 2 % agarose gels in the presence of the Midori Green DNA stain (Nippon Genetics, Japan) and subsequently visualized under UV light illumination. The resulting electrophoregrams were interpreted as previously \[[@CR17]\]. In the case of the cell lines, the presence of the band only in the reaction with the starters specific for the unmethylated sequence was treated as lack of gene methylation (U), whereas the presence of the band only in the reaction with the starters specific for the methylated sequence was treated as full gene methylation (M). Partial methylation (M/U) was detected when bands were observed in both reactions. Because DNA samples extracted from tumor sections cannot be treated as derived from a rather homogenous population of cancer cells (as in the case of cell lines), thus a simplified interpretation was used. Gene methylation (M) was detected in each case when the band in the reaction with the starters specific for the methylated sequence was present. Lack of gene methylation (U) was detected in each case when the band in the reaction with the starters specific for the methylated sequence was missing and only the band in the reaction with the starters specific for the unmethylated sequence was present.Table 3Sequences of the starters used in methylation-specific PCR designed using MethPrimerGeneSequenceTa*CXXC4*MF5′ GGAGAGAGAGAGGAGAGATTTTTC 3′60 **°**CMR5′ ATAAAAACGCGAATCTATTATCGAT 3′UF5′ AGAGAGAGAGGGAGAGATTTTTTGG 3′56 **°**CUR5′ ATAAAAACACAAATCTATTATCAAT 3′*FBXW11*MF5′ TAGGAAGTTAAGAGAAGTTAGTCGG 3′59 **°**CMR5′ CACTAAACGATAAACGTAAAACGTA 3′UF5′ TAGGAAGTTAAGAGAAGTTAGTTGG 3′59 **°**CUR5′ CACTAAACAATAAACATAAAACATA 3′*SUFU*MF5′ GTTTCGGGGAGTTTTATTTATC 3′*60 °C*MR5′ GAAAACCGAAAAAACAATCG 3′UF5′ GTTTTGGGGAGTTTTATTTATTGA 3′*60 °C*UR5′ AAACAAAAACCAAAAAAACAATCA 3′*ZIC1*MF5′ TTTCGTTAAACGTTTATTCGTTTC 3′62 **°**CMR5′ CACCTAACCTCCTAAAAACCTACG 3′UF5′ TTTGTTAAATGTTTATTTGATTTTGT 3′54 **°**CUR5′ TCACCTAACCTCCTAAAAACCTACA 3′*ZIC4*MF5′ CGGTTCGGTTAGGAAATTTATC 3′62 **°**CMR5′ AACCAAAAAAACGAAAAACGAC 3′UF5′ AGGTGGTTTGGTTAGGAAATTTATT 3′60 **°**CUR5′ AAAAACCAAAAAAACAAAAAACAAC 3′*M* methylated, *U* unmethylated, *F* forward, *R* reverse, *Ta* annealing temperature

Quantitative PCR {#Sec6}
----------------

Standard phenol/guanidine thiocyanate extraction protocol served for the preparation of total RNA samples from early passage cell lines. An RNA sample isolated from first passage primary oral keratinocytes (ScienCell Research Laboratories, USA) was used as a calibrator in gene expression quantification. All RNA samples were reverse transcribed using the RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific) according to manufacturer's protocol. Primer sequences for the analysis of the transcript level of *CXXC4*, *DACT2*, and *HHIP* were designed using the Beacon Designer software and further BLAST searched to minimize non-specific binding. Each primer pair covered a region spanning two distinct exons. The sequences are listed in Table [4](#Tab4){ref-type="table"}. Quantitative real-time PCR reactions were performed in a Chromo4 thermal cycler (Bio-Rad Laboratories, USA) using the HOT FIREPol Eva Green qPCR Mix (Solis BioDyne, Estonia). The amplification protocol was as follows: initial enzyme activation for 15 min at 95 °C followed by 40--45 cycles of 95 °C for 20 s, *X*°C for 20 s and 72 °C for 40 s, and the final elongation at 72 °C for 5 min, where *X* stands for the annealing temperature as described in Table [4](#Tab4){ref-type="table"}. Subsequent melting curve analysis allowed the confirmation of the presence of a single product. Measurements were performed in duplicate, and mean values were normalized using *PBGD* (*porphobilinogen deaminase*) as the reference gene. Relative expression level was calculated with the ΔΔCt method using the formula: RE = 2 ^\[Ct(ref) − Ct(test)\ TUMOR\]^/2 ^\[Ct(ref) − Ct(test)\ normal\ keratinocytes\]^.Table 4The sequence of starters used in real-time PCR analysisGeneStarter sequenceAmplicon sizeAnnealing T*CXXC4*F5′ CACCTCCTCCTCCTTCCAC105 bp56 °CR5′ GCATTATCCTCCAACTGTTACAAC*DACT2*F5′ CAGGCTTTTACGAGATGAG89 bp56 °CR5′ CAGCGAGGGAGAGATGTG*HHIP*F5′ TCCTATACCACCAACCAAGAAC165 bp59 °CR5′ TTGTCCTCCCAGATGCTTTC*PBGD*F5′ TCAGATAGCATACAAGAGACC111 bp56 °CR5′ TGGAATGTTACGAGCAGTG*F* forward primer, *R* reverse primer

Statistical analysis {#Sec7}
--------------------

The association between clinicopathological variables and the occurrence of single gene methylation was analyzed using chi-square or Fisher's exact tests. The association between clinicopathological variables and methylation index was analyzed using the Mann-Whitney *U* test or Kruskal-Wallis test. The analysis of the association of single gene methylation with overall survival time was performed using the *F*-Cox test. Multiple regression analysis allowed for the establishment of the association between methylation index and overall survival time. All the analyses were performed using the STATISTICA 10 software (StatSoft, Poland), and differences between groups were considered significant when *p* ≤ 0.05.

Results {#Sec8}
=======

In the screening stage, the analysis of the occurrence of promoter methylation of the studied genes in DNA samples derived from head and neck squamous cell carcinoma cell lines allowed for the identification of those genes which undergo methylation in these tumors. No methylation was detected for *FBXW11*, *PTCH1*, or *SUFU* while all the other genes showed relatively low (*DACT2*) to high (*ZIC1*) frequency of methylation in the tested cell lines except *HDPR1*, which was only partly methylated in two cell lines (Table [5](#Tab5){ref-type="table"}). Representative electrophoregrams are shown in Fig. [1](#Fig1){ref-type="fig"}. There was no statistically significant difference in the frequency of gene methylation between laryngeal and oral cavity and oropharyngeal carcinoma cell lines. Importantly, none of the genes was methylated in genomic DNA derived from normal oral keratinocytes or tracheal epithelial cells indicating that the methylation of *CXXC4*, *DACT2*, *HHIP*, *ZIC1*, and *ZIC4* does not appear in normal epithelial cells. We also wanted to assess whether the methylation of gene promoter regions under analysis correlated with their transcriptional activity. Therefore, we analyzed the expression of those genes which showed differential methylation status among the cell lines (Fig. [2](#Fig2){ref-type="fig"}). The expression of these genes in normal human oral keratinocytes (HOK) served as the reference in quantification. The quantitation of the transcript level of *CXXC4* and *HHIP* showed that full gene promoter methylation correlated with decreased level of expression when compared to expression in normal oral keratinocytes. The expression of these genes in cell lines showing only partial methylation or lack of methylation was not suppressed. This indicates that promoter methylation of these genes is associated with loss of their expression in HNSCC cells. Such an association was not observed in the case of *DACT2*, where the transcript level was similar irrespective of its methylation status indicating that the methylation of the analyzed promoter region is not the decisive factor in establishing transcription intensity.Table 5The frequency of gene promoter methylation in head and neck squamous cell carcinoma cell linesGeneMethylation statusFrequency (%)GeneMethylation statusFrequency (%)*CXXC4*M17.2*HHIP*M27.8M/U22.8M/U30.5U60U41.7*DACT2*M11.4*ZIC1*M88.9M/U14.3M/U14.3U74.3U2.8*HDPR1*M/U5.7*ZIC4*M22.2U94.3M/U47.2*FBXW11*U100U30.6*PTCH1*U100*SUFU*U100*M* full gene methylation, *M/U* partial methylation of gene, *U* complete lack of gene methylation Fig. 1Representative electrophoregrams for the analysis of *CXXC4, DACT2, FBXW11, HDPR1, HHIP, PTCH1, SUFU, ZIC1*, and *ZIC4* methylation by methylation-specific PCR using starters specific for the methylated sequence (M) and starters specific for the unmethylated sequence (U) in head and neck squamous cell carcinoma cell lines and control DNA samples: *HOK* DNA isolated from healthy oral keratinocytes, *MET* completely methylated human DNA, *WBC* DNA derived from white blood cells of healthy blood donors Fig. 2Relative expression levels of *CXXC4*, *DACT2*, and *HHIP* in HNSCC cell lines. The relative level of transcript was calculated as fold difference in relation to the expression in normal human keratinocytes (where expression was adopted as equal 1). The range of relative gene expression among cell lines (minimum and maximum values) and the mean level of relative expression (indicated in the graphs by the *arms* and the *green box*, respectively) in cell lines characterized by complete gene methylation (M), partial methylation (M/U), or lack of methylation (U) is shown

Based on the findings that *CXXC4*, *DACT2*, *HHIP*, *ZIC1*, and *ZIC4* are methylated in HNSCC cell lines and that their methylation is not present in normal oral and tracheal epithelium, we further investigated the frequency of methylation of these genes in laryngeal and oral tumor samples and matched surgical margin samples of OSCC patients. Exemplary electrophoregrams are shown in Fig. [3](#Fig3){ref-type="fig"}, and the summary of the results is presented in Table [6](#Tab6){ref-type="table"}. The rate of methylation of *ZIC1, ZIC4*, *HHIP*, and *DACT2* in tumors was very high, while methylation of *CXXC4* was low to moderate in OSCC and LSCC. Laryngeal tumors showed generally higher rates of gene methylation than oral cancers. Gene methylation was detected in all LSCC samples. The concurrent methylation of four genes was observed most frequently (43.7 %) followed by the observation of concurrent methylation of all five genes (23.3 %). The remaining cases showed the methylation of either three (20 %) or two (10 %) genes. Thus, the mean methylation index (MI---number of methylated genes divided by the number of all the tested genes) in LSCC samples was high---0.78. The occurrence of gene methylation was also highly prevalent among OSCC samples with only three cases showing the lack of methylation of any of the tested genes. Two OSCC cases showed the methylation of all five genes. The concurrent methylation of three genes was observed most frequently (26.2 %) followed by the concurrent methylation of two or four genes (23.8 %) or the methylation of a single gene (14.3 %). The mean methylation index in OSCC samples was 0.56. The frequency of methylation of the analyzed genes in OSCC surgical margin samples was lower than in the corresponding tumor samples what was reflected by a lower MI value of 0.4. The analysis of concordance (presence or lack of methylation in both paired samples) or discordance (presence of methylation in only one paired sample) of the results between paired tumor and surgical margin in OSCC patients is presented in Table [7](#Tab7){ref-type="table"}. Most discordant results were associated with the lack of gene methylation in the resection margin.Fig. 3Representative electrophoregrams for the analysis of *CXXC4, DACT2, HHIP, ZIC1*, and *ZIC4* methylation by methylation-specific PCR using starters specific for the methylated sequence (M) and starters specific for the unmethylated sequence (U) in laryngeal tumor samples (patients no. 78, 79, 82, 83, 113) and control DNA samples: *MET* completely methylated human DNA, *WBC* DNA derived from white blood cells of healthy blood donors Table 6The frequency of gene promoter methylation in tumor and resection margin of HNSCC patients*CXXC4* (%)*DACT2* (%)*HHIP* (%)*ZIC1* (%)*ZIC4* (%)LSCC36.696.79086.778.6OSCC105362.510073.2OSCC margin5.939.4409055.5 Table 7The concordance of gene promoter methylation in tumor and resection margin of OSCC patients*CXXC4* (%)*DACT2* (%)*HHIP* (%)*ZIC1* (%)*ZIC4* (%)T+ R+03123.789.551.4T+ R*−*5.917.236.810.522.8T*−* R+5.910.318.405.7T*−* R*−*88.241.421020*T* tumor, *R* resection margin, *+* presence of gene methylation, *−* lack of gene methylation

The presence of gene methylation in tumor samples did not correlate with histological grade or tumor size. However, the presence of *ZIC4* methylation in oral tumors significantly correlated with lymph node invasion (*p* = 0.041). The methylation of *ZIC4* in tumors did not correlate with the overall survival of patients (Fig. [4](#Fig4){ref-type="fig"}) although there was a trend for an association between *ZIC4* methylation and shorter survival in OSCC patients (*p* = 0.09088). Moreover, the MI value in oral tumor samples moderately correlated with the overall time of survival in the subgroup of 18 patients who died of the disease (*r* = 0.46, *p* = 0.05). The presence of gene methylation in OSCC surgical margin did not show any statistically significant correlation with clinicopathological variables. However, the MI value was higher in the case of patients who developed second primary tumors. Although such an association was noted, it has to be considered dubious since there were only two patients in the studied group who developed a second primary tumor during follow-up observation.Fig. 4Overall survival estimated by *ZIC4* methylation detected in tumors of oral (OSCC) and laryngeal (LSCC) cancer patients. *M* patients showing *ZIC4* methylation; *U* patients showing lack of *ZIC4* methylation

Discussion {#Sec9}
==========

Head and neck cancers are preventable tumors which develop mostly due to prolonged exposure to cigarette smoke and alcohol or HPV infection. In many cases, the tumor is diagnosed at a late stage when even aggressive treatment frequently fails to provide positive effects what results in low relapse-free and overall survival rates in patients with regional and distant head and neck carcinoma. Only recently, molecularly targeted therapies with EGFR (epithelial growth factor receptor) inhibitors have been applied with moderate outcomes in HNSCC indicating the need for the search of other therapeutic strategies. The increasing understanding of the molecular landscape in HNSCC points to several signaling pathways as drivers of the oncogenic transformation. Among those pathways, Wnt and Shh signaling seem especially interesting because of the possible association between their deregulation and disease progression. Infrequent mutations of members of these pathways and evidence of epigenetic silencing of their negative regulators stimulate the focus on the epigenetic mechanisms of modulation of the activity of these pathways in HNSCC.

Previous studies have shown that the enhanced transcriptional activity of β-catenin which is a marker of the activated canonical Wnt signaling is causally related to increased cell proliferation, migration, and epithelial-to-mesenchymal transition in HNSCC \[[@CR9], [@CR10]\]. Thus, the inhibition of β-catenin resulted in diminished cell growth and motility \[[@CR19]\]. The hypermethylation of such negative regulators of Wnt pathway as *SFRP1--5*, *DKK1--3*, *WIF1*, *DACH1*, and *PPP2R2B* may significantly contribute to pathway activation and was frequently observed in HNSCC \[[@CR15]--[@CR18]\]. Moreover, both the increased expression of pathway components and the methylation of several antagonists correlated with worse prognosis. Based on these previous findings that the methylation of Wnt antagonists may have diagnostic significance, we decided to analyze the methylation of other genes (*CXXC4*, *DACT2*, *HDPR1*, *FBXW11*) which were not studied in this context in HNSCC. Wnt signaling is antagonized by DACT2 and HDPR1 proteins due to their ability to bind Disheveled and thus prevent the destabilization of the β-catenin inhibitory complex. The methylation of *DACT2* was previously reported in lung and also in gastric and thyroid cancers where it correlated with tumor differentiation and invasion \[[@CR32], [@CR36], [@CR37]\]. On the other hand, *HDPR1* (*DACT1*) was downregulated by DNA methylation in breast or hepatocellular carcinoma \[[@CR33], [@CR38]\] and its downregulation was associated with poor prognosis in gastric and non-small cell lung cancers \[[@CR39], [@CR40]\]. Recently, it has been reported that both *DACT1* and *DACT2* are methylated in oral squamous cell carcinoma \[[@CR41]\]. *CXXC4* encodes Idax protein which also antagonizes Wnt signaling by interacting with Disheveled. Its epigenetic downregulation led to the activation of Wnt signaling and was associated with poor outcome in gastric cancer patients \[[@CR42]\]. *FBXW11* encodes one of the components of the complex responsible for the ubiquitylation of β-catenin leading to its subsequent degradation, and to our knowledge, the methylation of this gene has not been studied in cancer so far, but the promoter region of this gene contains a CpG island which possibly may become methylated. In our current study, the methylation of *HDPR1* was marginal in the HNSCC cell lines; thus, it was not further investigated in the group of HNSCC patients. Similarly, we did not detect the methylation of the promoter region of *FBXW11* in any of the tested HNSCC cell lines and thus did not investigate it further. On the other hand, we have observed that *DACT2* is frequently methylated in both the cells lines and head and neck carcinomas while *CXXC4* is methylated to a lesser extent. Moreover, their methylation is not observed in normal epithelial cells derived from healthy subjects. However, the methylation of *DACT2* or *CXXC4* did not significantly correlate with the clinicopathological features of the patients.

Few studies investigated the epigenetic regulation of Shh signaling in head and neck carcinomas; thus, we aimed to assess whether known negative regulators of this pathway (*HHIP*, *PTCH1*, *SUFU*, *ZIC1*, *ZIC4*) undergo methylation in HNSCC. HHIP inhibits Shh signaling by sequestering Hh ligands which then cannot activate the pathway, and its epigenetically mediated downregulation was observed in gastrointestinal, hepatocellular, and pancreatic tumors \[[@CR43]--[@CR46]\]. *PTCH1* blocks pathway activity in non-stimulated cells, and its loss due to methylation was observed in breast and gastric cancers and colorectal precancerous lesions \[[@CR35], [@CR46]--[@CR48]\]. SUFU blocks the pathway by sequestering Gli transcription factors in the cytoplasm, and to our knowledge, its methylation has not been studied in cancer so far. *ZIC1* and *ZIC4* antagonize the transcriptional activity of Gli. Previous studies have shown that *ZIC1* is frequently methylated in colorectal, hepatocellular, and gastric cancers \[[@CR49]--[@CR51]\] while the methylation of *ZIC4* was observed in bladder cancer \[[@CR52]\]. In our study, we have found lack of methylation of *PTCH1* or *SUFU* and frequent methylation of *HHIP*, *ZIC1*, and *ZIC4* in HNSCC. The observed lack of methylation of *PTCH1* is in contrast to a recent finding where restriction analysis of promoter methylation showed that this gene is methylated in many dysplastic lesions and nearly half of HNSCC cases \[[@CR53]\]. Methodological differences may be one possible source of this discrepancy. Another study reported that *ZIC4* is methylated in a quarter of HNSCC cases \[[@CR54]\]. To our knowledge, the methylation of *HHIP* has not been studied in HNSCC; however, it was reported that the expression of the encoded protein is lost in the majority of oral squamous cell carcinomas \[[@CR55]\]. Thus, our observation that *HHIP* undergoes methylation may partly explain the mechanism of this loss in head and neck cancers. Importantly, *ZIC4* methylation in tumors significantly correlated with lymph node invasion implicating that it might be considered a prognostic biomarker. Assuming that *ZIC4* methylation leads to the upregulation of Gli1 signaling, it may be hypothesized that it would contribute to the induction of epithelial-to-mesenchymal transition what subsequently results in increased cell motility and invasion. Indeed, the enhancement in Shh-Gli1 signaling induced migration of pancreatic cancer cells \[[@CR56], [@CR57]\].

Epigenetic studies using DNA methylation-based markers frequently indicated that the use of a panel of genes has stronger diagnostic significance in comparison to single gene testing. In this regard, the panel consisting of *CXXC4*, *DACT2*, *HHIP*, *ZIC1*, and *ZIC4* is a promising starting point for the development of a prognostic epimarker panel based on the finding that the MI value in tumor samples moderately correlated with the overall time of survival in the subgroup of 18 OSCC patients who died of the disease. Interestingly, the observed MI value in the surgical margin was higher in the case of OSCC patients who developed second primary tumors. Although this should be interpreted with great caution due to a low number of patients who developed second primary tumor during follow-up, this would be in agreement with the field carcinogenesis model which assumes that a diversity of molecular changes is detectable in a broad field of affected mucosa what may predispose cells to further neoplastic transformation \[[@CR58], [@CR59]\]. In line with this model, epigenetic changes were observed not only in tumor sections but also in macroscopically normal surgical margin. The presence of epigenetic aberrations in surgical margin and distant mucosa in HNSCC is well documented \[[@CR16], [@CR60], [@CR61]\]. These changes may constitute both part of the field of preneoplastic molecular alterations and be related to the presence of single neoplastic cells which are usually not detected under standard histopathological examination \[[@CR61]\].

In summary, we report that *CXXC4*, *DACT2*, *HHIP*, *ZIC1*, and *ZIC4* are methylated in head and neck squamous cell carcinomas. These findings corroborate that the activation of Wnt signaling in HNSCC is related to epigenetic silencing of the negative regulators of this pathway. Moreover, the results of our study indicate that the same mechanism of activation may operate in the case of Shh signaling. In this regard, functional studies should follow to investigate whether epigenetic modulators may inhibit Wnt or Shh signaling due to the reactivation of expression of pathway antagonists. Additionally, we conclude that the methylation of *ZIC4* may be considered a new prognostic marker in HNSCC. Further investigations should determine the detailed diagnostic significance of methylation of *ZIC4*, *HHIP*, and *DACT2* in head and neck carcinomas.

HNSCC

:   Head and neck squamous cell carcinoma

LSCC

:   Laryngeal squamous cell carcinoma

OSCC

:   Oral squamous cell carcinoma
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